Aug 20, 2014|
Dr. Janne's main research includes the study of epidermal growth factor receptor mutations (EGFR) in non-small cell lung cancer patients. He and other researchers at Dana-Farber showed that patients whose tumors had a malfunctioning version of the EGFR protein responded dramatically to a drug that specifically targets the EGFR protein. The findings launched the era of precision medicine for lung cancer, transforming the way the disease is treated in many patients.
Transcript - will not be 100% accurate
I would wanna bring on now one of the doctors who helps make people like -- and -- Better that's doctor -- he Johnny from the boat's owner of the rustic oncology. At Dana Farber. This we -- -- all fifty states according to people from Finland. Orioles in Harlem right and we had -- asked yesterday and our second Finnish hockey player is here today when -- -- on middays with them happy doctor thanks for coming by my -- tell -- little bit about what you do with the Dana Farber cancer institute and the Jimmy Fund and how you're helping patients like -- -- we've talked to today I direct the island cancer program and after -- last year. Also work as one cancer researcher trying to understand. What -- -- cancers happen how we can understand -- particular -- -- the races those cancers ultimately how we can use that biological understanding to develop their. There's way out it will when I read. But it you need to study up at the durable growth factory sector mutations. And go to EGF are. What is that they cricket coach I was a little bit what you thought about it a college course that you would never take grave -- -- that this is this is for example we called personalized or precision that is -- lung cancer this discovery were involved in over a decade ago. It basically the finding was that there's certain pieces with lung cancers. All hole normally have this GPs. That the -- but it's found to be mutated altered just in the cancer. Pitches. It -- this alteration there's specific drugs actually work incredibly well. Now are approved by the Food and Drug Administration specifically for this typical race. Yeah you know we talk about your lung cancer all it is that the smoker figures smoker's lung cancer that's not related cases. Not the case about 1520%. That pieces of it excellent cancer word and act like one never smokers. And -- a significant proportion of the ones that did it diagnosed. Used to smoke acquitted in the right to their doctors they -- 2030 years ago but still at risk of bill. What do when I read it lung cancers leading cause for cancer death. Among men and women. Is that because there's so much of it or -- because that it's one of the toughest ones to fight. It is not the most common cancer but it is that once it's one of the toughest ones fight. And you're right is the cause of cancer death for those men and women. In those numbers that are slowly started to change. Partly because as we treat the cancer an honest one disease that we find different segments of the disease like the ones via -- growth factors are -- others. Developed specific treatments for these different substance -- making all the substances that are we can make the cancer better as well. -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- And outs in the funds that were raised and today it to be practical application of making people better. Now and talk to my dad last minute tried to get the pathway here maybe you can help me a little bit more with the bill for institute talked to me about that. And how it helps people's rights also help co direct typical -- raised him for applied cancer science with the -- one the other co director. And this is an institute where were trying to -- Basic scientific discoveries and really translated really easy to do they have any -- An opportunity or are potential to develop therapies. We work with the department investigators work with pharmaceutical companies have drugs but that is so weird put those -- What's the right -- substance under the right companies and we help bring those two worlds again we help reach. The development process with the idea that ultimately. We want to accelerate the path from scientific discovered -- it's real. We'll have a single goal line that is to develop better therapies for patients to orbit can be cured or live longer. And that's what the golfers. And as suggests research argue actually do you have patient that you see in a regular basis than an off a huge economic team an -- Simon adult ecologists IDC pacers 11 pulled it -- -- and -- spend the rest of the time in various research activities I'll have Belfort. And for me I love the next I love the ability to. Think about science think about it -- nations but ultimately I love seeing peace as well because -- think here you get a real world understanding of why -- successful ultimately why did they lose their success and -- those insights from the clinic. That didn't inspire me to go back to collapse -- we can develop better treatments. We can take back to the pace that that's the part that's gratifying -- work and arbor so last genetics questioned genetically speaking why there's so many good goaltenders from Finland. It's in the -- not talent at Dynegy. It's not telling us earlier radically different position now and -- medical and it must play offense but that the right there look at it either somebody defends the shootout -- and other. He did a study the genes that are all well it's all the -- migrants. We're not thanks so much they don't know that's right guys appreciated and thanks for the good work you do on -- on my pleasure.